Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Betmigatm receives CHMP recommendation to treat OAB syndrome
The recommendation requires to be ratified by decision of the European Commission which is expected within the next 74-90 days and if approved Betmigatm will be a new
The recommendation requires to be ratified by decision of the European Commission which is expected within the next 74-90 days and if approved Betmigatm will be a new
The TOURMALINE-AL1 multi-centre study will assess once-weekly oral MLN9708, a proteasome inhibitor, in combination with dexamethasone. Millennium chief medical officer Karen Ferrante said, "The MLN9708 amyloidosis trial employs
The multi-centre, open-label, early stopping design study will measure the clinical activity of Tasquinimod by the section of patients with progression free survival at pre-defined time-points. Ipsen R&D
Australian-based Dynamiclear’s product is intended for symptomatic treatment of cold sores and fever blisters in just one application. A 150 patient-based clinical trial showed that by day three
Gonax is designed to inhibit the binding of GnRH, a hormone produced by the hypothalamus in the brain, to the specific receptors thereby restraining the testosterone production and
The European Commission is yet to approve the product that should be used in combination with a clinical evaluation. Amyvid global brand leader Diane Bakaysa said, "If approved
Under the LOI, Abattis has gained rights to acquire the area of BC to a BioPharma license and the Vertical Design’s equipment. Abattis president and CEO Mike Withrow
The collaboration will leverage Fragment Evolution (FE) technology that was developed by Astellas using small molecular weight fragments and the technologies gathered by AIST for the construction of
The new company, CSafe, as result of the merger, is expected to be the only global provider of cold chain solutions including packaging, passive systems, active systems, with
Tris Pharma corporate development vice president Peter Ciano was quoted by NJBIZ as saying that the recently received FDA approval for a product is expected to add another